Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 7/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | USP8 | P40818 | 1/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.37 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3291131 | 0.88 | ADORA1 (0.46) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2650903 | 0.85 | GABRG2 (0.47) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2649411 | 0.85 | GABRG2 (0.45) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL3296198 | 0.82 | CHUK (0.45) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL2649508 | 0.81 | GABRG2 (0.45) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL3287557 | 0.81 | SCN9A (0.46) | SQORPDE4B | |
| SCHEMBL2649739 | 0.79 | MAPT (0.50) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL3287308 | 0.79 | UGCG (0.46) | SQORPDE4B | |
| SCHEMBL2652445 | 0.78 | CYP11B2 (0.40) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL3290564 | 0.78 | CYP11B2 (0.39) | GABRG2GABRB3GABRA5GABRA3GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546374-B2 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-12-27 | — | — | US | disclosed |
| US-8217067-B2 | Antiinflammatory agents, antidepressants, analgesics, purinergic receptor antagonists; neurodegenerative diseases, spinal cord injuries; 1-(2,3-dichlorophenyl)-N-[(2-methylphenyl)methyl]-1H-tetraazol-5-amine | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| US-7723367-B2 | Amino-tetrazoles analogues and methods of use | ABBOTT LABORATORIES (US) | 2010-05-25 | — | — | US | disclosed |
| US-7704997-B1 | Amino-tetrazole analogues and methods of use | ABBOTT LABORATORIES (US) | 2010-04-27 | — | — | US | disclosed |
| US-20080171733-A1 | Amino-Tetrazoles Analogues and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-17 | — | — | US | disclosed |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1747206-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | ABBVIE INC. | 2006-03-09 | — | — | US | disclosed |
| WO-2005111003-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171733-A1 | Amino-Tetrazoles Analogues and Methods of Use | P2RX7, P2RX2, P2RX5 | GABRG2 419/4885GABRB3 100/4885GABRA5 135/4885 |
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | P2RX7, P2RX2, P2RX5 | GABRG2 419/4885GABRB3 100/4885GABRA5 135/4885 |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | P2RX7, P2RX2, P2RX5 | GABRG2 419/4885GABRB3 100/4885GABRA5 135/4885 |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | P2RX7, P2RX2, P2RX3 | GABRG2 410/4885GABRB3 89/4885GABRA5 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.